Clinical Trials Logo

Lymphoma, Follicular clinical trials

View clinical trials related to Lymphoma, Follicular.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05107856 Terminated - Clinical trials for Acute Myeloid Leukemia

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies. The purpose of this study is to evaluate the safety and tolerability of PRT1419 monotherapy and in combination with either azacitidine or venetoclax, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

NCT ID: NCT04762160 Terminated - Follicular Lymphoma Clinical Trials

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Start date: December 15, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1 anti-CD20-based regimen was used.

NCT ID: NCT04699461 Terminated - Clinical trials for Refractory Follicular Lymphoma

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

LOTIS-6
Start date: November 4, 2021
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.

NCT ID: NCT04590820 Terminated - Lymphoma Clinical Trials

Oral Tazemetostat in Combination With Rituximab in R/R FL

Start date: November 17, 2020
Phase: Phase 2
Study type: Interventional

The goal of this study is to examine the feasibility and efficacy of adding the EZH2 inhibitor, Tazemetostat to rituixmab, standard second line or beyond therapy as a means to improve disease response.

NCT ID: NCT04342117 Terminated - Lymphoma Clinical Trials

Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

REAL
Start date: April 23, 2020
Phase:
Study type: Observational [Patient Registry]

This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.

NCT ID: NCT04156828 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Start date: March 31, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose of copanlisib when given together with combination chemotherapy (R-GCD) in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or grade 3b follicular lymphoma that has come back (relapsed) after 1 prior line of therapy. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine, carboplatin, and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving copanlisib together with R-GCD as second line therapy may improve the complete response rate for patients with diffuse large B-cell lymphoma or follicular lymphoma.

NCT ID: NCT03890289 Terminated - Follicular Lymphoma Clinical Trials

Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

GAUDEALIS
Start date: October 18, 2019
Phase: Phase 2
Study type: Interventional

Single arm, prospective, multi-centric, phase II study. Patients with histologically confirmed follicular lymphoma, in need of a systemic approach and failing (i.e. with refractory disease [no response or response lasting less than 6 months at any previous line of treatment] or with a proven disease relapse) at least 2 previous lines of treatment, including any antibody directed against the CD20 antigen-containing chemotherapy, will undergo a combined chemo-free treatment with obinutuzumab and idelalisib.

NCT ID: NCT03828448 Terminated - Follicular Lymphoma Clinical Trials

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

Start date: July 10, 2019
Phase: Phase 2
Study type: Interventional

This is a phase 2, open label study to assess umbralisib in combination with ublituximab in participants with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).

NCT ID: NCT03768505 Terminated - Clinical trials for Non Hodgkin Lymphoma

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Start date: June 25, 2019
Phase: Phase 2
Study type: Interventional

This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy

NCT ID: NCT03685344 Terminated - Clinical trials for Mantle Cell Lymphoma

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Start date: February 4, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this phase 1 study is to evaluate the safety and anti-tumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in participants with Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma